GlassScriptPhysician profile
Alisa Davidova
NPI 1639755457
$2,067.87
in general payments reported to CMS, 2019-2025
16 companies · $988 in 2025
The $988 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $336 · 2024: $744 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $372.81 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.07 | 2023-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $225.13 | 2024-2025 | |
| Abbvie INC. | $202.82 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $166.57 | 2023-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $153.44 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $141.23 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $101.10 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $67.51 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $66.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $61.77 | 2024-2025 | Iqirvo, Bylvay |
| Braintree Laboratories, INC. | $46.09 | 2023-2024 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $38.58 | 2024-2025 | Dupixent |
| Exact Sciences Corporation | $27.50 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2023 | Cyltezo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $16.65 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisa Davidova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.